Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQ3O1U)

• Drug Name: ABT-165 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMQ3O1U

Molecule-Related Drug Atlas

Drug(s) Targeting Delta-like protein 4 (DLL4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dilpacimab	DMCATH2	Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]
Navicixizumab	DMZ2G69	Colorectal cancer	2B91.Z	Phase 1	[3]
NOV1501	DME2QUZ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
REGN-421	DMWJ0IH	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
OMP-21M18	DMX1D0S	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]

Drug(s) Targeting Vascular endothelial growth factor (VEGF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Brolucizumab	DMW8QNG	Wet age-related macular degeneration	9B78.3Z	Approved	[7]
Squalamine	DM3PS2E	Solid tumour/cancer	2A00-2F9Z	Phase 3	[8]
PF-06439535	DMVHZDP	Non-small-cell lung cancer	2C25.Y	Phase 3	[9]
M710	DM1PRT6	Diabetic macular edema	9B71.02	Phase 3	[10]
FKB238	DM6R2XF	Non-small-cell lung cancer	2C25.Y	Phase 3	[11]
KSI-301	DMM2LTC	Diabetic macular edema	9B71.02	Phase 3	[12]
TRS003	DMM1VOH	Colorectal cancer	2B91.Z	Phase 3	[13]
MYL-1402O	DMXN2PP	Non-small-cell lung cancer	2C25	Phase 3	[14]
SB15	DMTOS6C	Neovascular age-related macular degeneration	9B78.3Z	Phase 3	[15]
Dilpacimab	DMCATH2	Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Delta-like protein 4 (DLL4)	TTV23LH	DLL4_HUMAN	Inhibitor	[1]
Vascular endothelial growth factor (VEGF)	TT9HKJA	VEGFA_HUMAN; VEGFB_HUMAN; VEGFC_HUMAN; VEGFD_HUMAN	Inhibitor	[1]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Apoptogenic activity of 2alpha,3alpha-dihydroxyurs-12-ene-28-oic acid from Prunella vulgaris var. lilacina is mediated via mitochondria-dependent activation of caspase cascade regulated by Bcl-2 in human acute leukemia Jurkat T cells. J Ethnopharmacol. 2011 Jun 1;135(3):626-35.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer. BMB Rep. 2020 Nov;53(10):533-538.
• [5] J Clin Oncol 31, 2013 (suppl; abstr 2502).
• [6] National Cancer Institute Drug Dictionary (drug id 614677).
• [7] Brolucizumab: First Approval. Drugs. 2019 Dec;79(18):1997-2000.
• [8] Clinical pipeline report, company report or official report of Ohr Pharmaceutical.
• [9] National Cancer Institute Drug Dictionary (drug id 43234).
• [10] ClinicalTrials.gov (NCT03610646) Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea in Subjects With Diabetic Macular Edema. U.S. National Institutes of Health.
• [11] Clinical pipeline report, company report or official report of Fujifilm.
• [12] Clinical pipeline report, company report or official report of Kodiak Sciences.
• [13] Prevalence of porcine cysticercosis in Vellore, South India. Trans R Soc Trop Med Hyg. 2013 Jan;107(1):62-4.
• [14] MYL-1402O: A Bevacizumab Biosimilar. Target Oncol. 2022 Jan;17(1):85-88.
• [15] Efficacy and Safety of the Aflibercept Biosimilar SB15 in Neovascular Age-Related Macular Degeneration: A Phase 3 Randomized Clinical Trial. JAMA Ophthalmol. 2023 Jul 1;141(7):668-676.